Breaking Finance News

Portola Pharmaceuticals Inc (NASDAQ:PTLA) target price raised to $25.00, reported today by Zacks Investment Research

Boasting a price of $22.81, Portola Pharmaceuticals Inc (NASDAQ:PTLA) traded -1.66% lower on the day. The last stock close price is down -10.93% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $21.90 and a 200-day moving average of $23.94. 748,299 shares of PTLA traded, down from an avg. volume of 1,126,790

Portola Pharmaceuticals Inc (NASDAQ:PTLA) had its price target upped to $25.00 by Zacks Investment Research in an issued report released 10/5/2016. The new target price indicates a possible upside of 0.10% from the company's most recent stock close price.

On 8/19/2016, Citigroup Inc. released a statement about Portola Pharmaceuticals Inc (NASDAQ:PTLA) dropped the target price from $40.00 to $24.00. At the time, this suggested an upside of 0.25%.

Recent Performance Chart

Portola Pharmaceuticals Inc (NASDAQ:PTLA)

With a total market value of $0, Portola Pharmaceuticals Inc has with a one year low of $18.20 and a one year high of $52.89 .

A total of 5 equity analysts have released a research note on PTLA. 2 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $47.80.

About Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.